/ /

  • linkedin
  • Increase Font
  • Sharebar

    Aflibercept performance consistent in DME regardless of prior anti-VEGF therapy

    VISTA-DME/VIVID-DME trials evaluate efficacy of treatment with central involvement, BCVA

     

    Houston—Intravitreal aflibercept (Eylea, Regeneron Pharmaceuticals) seems to have similar efficacy in patients with diabetic macular edema (DME) who had been treated previously with anti-vascular endothelial growth factor therapy (VEGF) as in those with DME who were anti-VEGF treatment naïve.

    “The outcomes thus far from the VISTA-DME/VIVID-DME phase III trials indicate that the group treated with 2 mg of aflibercept every 8 weeks after 5 monthly doses had similar outcomes to the group treated with 2 mg of aflibercept every 4 weeks, regardless of prior anti-VEGF therapy,” said Charles C. Wykoff, MD, PhD.

    VISTA-DME/VIVID-DME

    The VISTA-DME/VIVID-DME study is a randomized, multicenter, double-masked trial that evaluated the efficacy of intravitreal injections of aflibercept in patients with clinically relevant DME that involved the central macula and best-corrected visual acuity (BCVA) of 20/40 to 20/320.

    The VISTA segment of the study included 466 U.S. patients, whereas the VIVID segment included 406 patients from outside the United States.

    Patients were randomly assigned either to focal macular laser photocoagulation or one of two doses of intravitreal aflibercept: 2 mg every 4 weeks or 2 mg every 8 weeks following 5 consecutive monthly doses, said Dr. Wykoff, who is in private practice, Houston.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results